

Docket No.: C035795/0126287

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Seth LEDERMAN and Christopher GAMPER

Serial No.: 09/930,864

Filed: August 16, 2001

For: **ISOLATED FRAGMENTS OF p62
NUCLEOPORIN AND USES THEREOF**

Examiner: Robert A. Wax

Art Unit: 1653

New York, New York
April 17, 2006

**RESPONSE TO RESTRICTION REQUIREMENT
AND PETITION FOR EXTENSION OF TIME**

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

This is in response to the Office Action mailed January 27, 2006, which set a one-month shortened statutory period for response. A two-month extension of time is hereby requested. Accordingly, this Response is timely filed with an executed certificate of mailing on or before April 27, 2006. See 37 C.F.R. §§ 1.8 & 1.136. Enclosed is a check in the amount of \$225.00 to cover the fee for the petition for extension of time for two months for a small entity. See 37 C.F.R. §1.17(a). Please charge any required extension-of-time fees not otherwise paid by check to Deposit Account No. 02-4467. A duplicate copy of this sheet is enclosed.

04/26/2006 MWOLDGE1 00000015 09930864

01 FC:2252


225.00 0P

On page 2-3 of the Office Action, the Examiner issued an eight-way restriction requirement pursuant to 35 U.S.C. §121. The restriction divided the claims into the following allegedly distinct inventions: Group I drawn to a "polypeptide having SEQ ID NO: 1 and pharmaceutical compositions thereof" (Claims 1-16); Group II drawn to "a method of inhibiting translocation of NF-6B across a nuclear membrane" (Claims 17 and 18); Group III drawn to "a method of inhibiting inflammation of tissue in a mammal" (Claims 19-22); Group IV drawn to a "polypeptide having SEQ ID NO: 2 and pharmaceutical compositions thereof" (Claims 23-39); Group V drawn to "a method of enhancing the activation of NF-6B in a mammalian cell" (Claims 40 and 41); Group VI drawn to "a method of enhancing an immune response in a mammal" (Claims 42-45); Group VII drawn to "a method of screening compounds using a polypeptide having SEQ ID NO: 1" (Claims 46-55); and Group VIII drawn to "a method of screening compounds using a polypeptide having SEQ ID NO: 2" (Claims 46-55).

In accordance with restriction practice, the subject matter of claims 1-16 (Group I) is hereby elected for prosecution with traverse.

If the Examiner has any questions regarding this paper, please contact the undersigned attorney.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450, on April 17, 2006.


Stephen J. Brown, Reg. No. 43,519

Respectfully submitted,

By: 

Stephen J. Brown
Registration No. 43,519
BRYAN CAVE LLP
1290 Avenue of the Americas
New York, NY 10104
Phone: (212) 541-2000
Fax: (212) 541-4630